How to Make a Biotech Pitch Deck [A Detailed Guide]
- Ink Narrates | The Presentation Design Agency
- Oct 11, 2022
- 7 min read
Updated: Aug 4
Craig, one of our clients, asked us something that instantly caught our team’s attention while we were building his biotech pitch deck.
“How do I explain complex science to people who don’t understand it but need to fund it?”
Our Creative Director replied without blinking:
“You translate science into money.”
As a presentation design agency, we work on many biotech pitch decks throughout the year. In the process, we’ve noticed one recurring challenge: biotech founders struggle to balance scientific depth with investor clarity.
So in this blog, we’ll show you how to create a biotech pitch deck that connects the dots between lab results and investment decisions.
In case you didn't know, we specialize in only one thing: making presentations. We can help you by designing your slides and writing your content too.
Why Biotech Pitch Decks Are So Difficult to Get Right
Let’s be honest—making a biotech pitch deck isn’t just about throwing some science on slides. It’s about selling a future that hasn’t happened yet, built on data that not everyone in the room fully understands.
We’ve seen this pattern too often. Founders walk into the pitch with real breakthroughs in molecular pathways or delivery mechanisms, but lose their audience somewhere between the mechanism of action and the p-values. Why? Because the typical biotech pitch deck tries to impress rather than connect.
Here are the usual suspects when things go sideways:
1. Too Much Science, Not Enough Story
Biotech founders are wired for accuracy. And while that’s great in a lab, it becomes a liability in front of VCs. Overloading the deck with dense scientific language or 10-year clinical pathways makes it feel like a conference paper, not a pitch.
2. No Clear Investment Hook
Investors aren't here for a biology lesson. They’re here to understand risk, upside and timeline. We’ve seen decks that detail gene editing methods in excruciating depth but skip the go-to-market strategy entirely. That’s a problem.
3. Unstructured Flow
If your deck jumps from the origin of your research to five-year projections and then back to mechanism of action, you’re not being thorough—you’re being confusing. Biotech decks often suffer from “intellectual zigzagging” that derails attention.
4. Visuals That Don’t Help
Biotech presentations often lean on generic academic diagrams or stock imagery that adds zero clarity. A poorly labeled pharmacokinetics graph is just noise unless the investor knows what they’re looking at. Most don’t.
5. Lack of Competitive Framing
Many founders believe their tech is novel—and it probably is. But without clearly positioning it against what already exists, you’re asking investors to guess what makes it fundable. That’s risky.
6. Unrealistic Timelines and Valuations
This one’s tough. We know early biotech is high-risk, high-reward. But skipping over the 8-year clinical journey or inflating early valuations without traction data can quietly kill credibility.
What all these challenges have in common is this: forgetting who the deck is really for. Your job is not just to inform, but to persuade.
How to Make a Biotech Pitch Deck That Works
Let’s get into it.
There’s a method to building a biotech pitch deck that doesn’t just dump information but walks investors through a story they want to say yes to. And no, this isn’t about dumbing things down. It’s about organizing your brilliance in a way that aligns with how people make decisions—especially people who write checks.
Here’s the structure we follow when building biotech pitch decks for our clients. We’re not just designing slides—we’re structuring narratives that take highly complex science and make it investable.
1. Start With a Straightforward Problem Slide
Biotech has a bad habit of overcomplicating the problem.
We’ve seen decks begin with an abstract pathway or a “scientific opportunity” that means nothing to someone outside the domain. That’s a mistake.
Start with what’s broken. Be blunt. What is the problem in the real world? What human consequence does it have?
For example:
“Current pancreatic cancer diagnostics detect tumors too late. As a result, survival rates remain under 10%.”
“The standard of care for pediatric epilepsy still relies on drugs developed in the 1980s, with poor outcomes and heavy side effects.”
Avoid leading with the science. Lead with the problem. The science comes next to prove your point.
2. Position Your Solution with Clarity, Not Complexity
This is where many biotech founders want to dive into mechanisms and preclinical data. Don’t.
First, answer this: what does your product do that nothing else can?
Use simple language. Not simplistic—just direct. Explain the result your tech achieves, not how it works yet.
Here’s a format that works: We’ve developed a [what it is] that [what it does].
Example: "We’ve developed a liquid biopsy test that can detect early-stage pancreatic tumors with 90% specificity.”
The science can follow in a supporting slide or appendix, but the main idea should be digestible in 15 seconds.
3. Explain the Science, But Know Where to Stop
Yes, you need a science slide. And yes, it needs to be technically sound. But here’s the catch: don’t assume you’re presenting to scientists.
Use diagrams and visuals that have a clear hierarchy. Walk the viewer through a process, don’t just paste a diagram from a paper.
What’s helpful:
Visuals that show “before and after” impact
Flowcharts of how your mechanism works in the body
Simple comparisons with current standards of care
What’s not helpful:
Cluttered molecular pathways
Slides with 200 words and 5 references
Color-coded heat maps with no legend
If your investor needs a PhD to get through the slide, they’re not going to ask for a second meeting. Make your science bulletproof, but don’t make it a trap.
4. Highlight Your Preclinical or Clinical Traction
This is where you bring out the data—but only if it builds trust.
What we’ve learned: data is persuasive when it’s comparative. Not when it’s floating in a vacuum.
Example of ineffective phrasing:“Our compound reduced tumor size in mice.”
Better phrasing:“Our compound reduced tumor size by 72% in 3 weeks—3x better than standard chemo—across 4 independent animal studies.”
Investors care about whether this thing is working better than the current reality. Even if you’re early stage, show progress in context.
Also, keep charts clean. One chart per slide is fine. You’re telling a story, not publishing a research paper.
5. Spell Out the Market Opportunity (But Be Realistic)
Biotech decks often pull a lazy trick here: “The global cancer market is $200B.” And? That doesn’t mean anything.
Investors want to know your addressable market, not the entire industry.
Use these distinctions:
Total Addressable Market (TAM): What’s the global market for the disease category?
Serviceable Available Market (SAM): What’s the market size you can realistically serve?
Serviceable Obtainable Market (SOM): What can you realistically capture in the next 5–7 years?
Example:“We’re targeting a $4B subset of the pancreatic cancer diagnostics market, with potential to capture $500M in revenue over 7 years through early detection partnerships.”
This is where credibility matters. Show how you arrived at the numbers. Show the math.
6. Explain the Business Model
Yes, you’re a biotech company, but you still need a business model. How do you make money?
For therapeutics:
Licensing to pharma after Phase I/II?
Direct commercialization?
Strategic partnerships?
For diagnostics:
Direct-to-provider?
B2B deals with health systems?
Licensing your platform?
Be specific. Avoid generic statements like “We’ll partner with big pharma.” Name who, explain why.
Also, if reimbursement is part of your model, show you’ve thought about payer dynamics.
7. Lay Out the Roadmap and Timeline
Every investor wants to know: where are you, and how long until this thing makes money?
Don’t overpromise. We’ve seen founders shave 2 years off regulatory timelines just to seem fast. That always backfires.
Show a visual roadmap:
Discovery
Preclinical
IND submission
Phase I, II, III
Regulatory approval
Commercialization
Include timeframes and rough capital needed at each stage. This helps investors understand your burn rate and funding plan.
And yes, if you’re preclinical, be honest about how far you are. Investors will respect transparency more than blind optimism.
8. Your Team Matters More Than You Think
Biotech is high-risk. Investors bet on people more than products.
Include key bios. Keep it short. Focus on relevance.
Things to highlight:
Past exits
Deep experience in biotech, pharma, or regulatory
Advisors with credibility in science or business
Cross-functional strength (you need both scientific and commercial brains)
Don’t list everyone on payroll. Highlight the 4–6 names that give confidence this team can pull it off.
And if there are gaps (e.g. no regulatory lead yet), just say you’re hiring. Hiding gaps kills trust.
9. Talk About Competition Like a Grown-Up
Most decks either ignore competitors or claim “we’re first.” Neither works.
Assume your investors already know who your competitors are. If you don’t mention them, it looks like you didn’t do your homework.
Use a visual comparison slide:
Table format
Columns for competitors
Rows for key differentiators (accuracy, delivery method, safety, etc.)
Your company as one of the rows
Be fair. Show where competitors are ahead. Show where you’re ahead. That’s real-world positioning.
Also, don’t just list what competitors lack—show why your solution wins in real-world adoption.
10. Financials & Ask
You don’t need a full P&L at seed or Series A. But you do need to show financial literacy.
Include:
How much you’re raising
What the funds will cover (clear use of proceeds)
Estimated runway
Key milestones tied to that funding
Example: “We’re raising $8M to complete IND-enabling studies and initiate Phase I trials, with 24 months of runway.”
Optional but helpful: a high-level 3–5 year financial projection showing burn, major cost centers, and expected inflection points.
11. End With the Vision Slide
We always recommend ending strong. Remind them what they’re buying into.
Reinforce the long-term impact:
“Changing how pancreatic cancer is detected.”
“Redefining the standard of care for pediatric epilepsy.”
“Turning fatal diseases into manageable conditions.”
Don’t be vague or poetic. Be bold and grounded in the science. Leave them with a future they can see and want to be part of.
Why Hire Us to Build your Presentation?
If you're reading this, you're probably working on a presentation right now. You could do it all yourself. But the reality is - that’s not going to give you the high-impact presentation you need. It’s a lot of guesswork, a lot of trial and error. And at the end of the day, you’ll be left with a presentation that’s “good enough,” not one that gets results. On the other hand, we’ve spent years crafting thousands of presentations, mastering both storytelling and design. Let us handle this for you, so you can focus on what you do best.